Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis
- 21 April 2000
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 395 (1) , 51-59
- https://doi.org/10.1016/s0014-2999(00)00219-3
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Inhibition of Factor Xa by a Peptidyl-α-ketothiazole Involves Two Steps. Evidence for a Stabilizing Conformational ChangeBiochemistry, 1999
- Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial ThrombosisThrombosis and Haemostasis, 1998
- Low molecular weight heparinsJournal of Internal Medicine, 1996
- Management of Deep Vein Thrombosis and Pulmonary EmbolismCirculation, 1996
- Surface-dependent reactions of the vitamin K-dependent enzyme complexesBlood, 1990
- RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.Journal of Clinical Investigation, 1989
- Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.Proceedings of the National Academy of Sciences, 1989
- Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.Proceedings of the National Academy of Sciences, 1988
- [63] Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketonePublished by Elsevier ,1981
- D-PHE-PRO-ARGCH2Cl-A selective affinity label for thrombinThrombosis Research, 1979